Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics said it reached a PBM agreement adding 24 million covered lives and a regional health plan update covering approximately 3 million lives, bringing ZELSUVMI formulary coverage to 127 million commercially covered lives. The company reiterated that ZELSUVMI is approved for adults and pediatric patients one year of age and older and highlighted safety and prescribing information in the release.